Loading...
Fondaparinux: Should It Be Studied in Patients with COVID-19 Disease?
Marongiu, Francesco Barcellona, Doris
Marongiu, Francesco
Barcellona, Doris
Citations
Altmetric:
Genre
Correspondence
Date
2020-10-01
Advisor
Committee member
Department
Subject
Permanent link to this record
Collections
Research Projects
Organizational Units
Journal Issue
DOI
http://doi.org/10.1055/s-0040-1719232
Abstract
We have read with interest the review article by Bikdeli et al recently published in Thrombosis and Haemostasis on the priority in planning studies on the different anticoagulants in coronavirus disease 2019 (COVID-19) infection.[1] The authors describe the characteristics of both the anticoagulants available today and in the future. Antiplatelets drugs have been also considered. Surprisingly, fondaparinux (FPX) has reached a lower priority research mean (4.89) than unfractionated heparin (UFH) and low-molecular weight heparin (LMWH) at intermediate (7.82) or therapeutic (7.53) dosage for hospitalized ward and intensive care unit patients. We believe that properties of these drugs have been overlooked by the scientific panel of the Global COVID-19 Thrombosis Collaborative Group.
Description
Citation
Citation to related work
Georg Thieme Verlag KG
Has part
TH Open, Vol. 4, Issue 4
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu